Royalty Pharma to Present at Upcoming Investor Conferences
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in early December 2025: Citi 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET and Evercore 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET.
The company said webcasts of both presentations will be available on its Events page and archived for a minimum of 30 days, allowing investors to view the presentations after the live sessions.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RPRX gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RPRX was up 0.45% while peers were mixed: BNTX -0.36%, GMAB +1.97%, INCY +1.22%, SMMT +0.78%, INSM +2.63%. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Royalty funding deal | Positive | -1.1% | Announced $275M synthetic royalty funding tied to Denali’s tividenofusp alfa. |
| Nov 26 | Investor conferences | Positive | +0.8% | Planned Citi and Evercore conference presentations with archived investor webcasts. |
| Nov 05 | Earnings results | Positive | +6.8% | Reported Q3 2025 growth and raised full‑year Portfolio Receipts guidance. |
| Nov 04 | Royalty acquisition | Positive | +1.4% | Acquired 1% AMVUTTRA royalty interest from Blackstone for $310M. |
| Oct 17 | Dividend declaration | Positive | +1.8% | Declared Q4 2025 dividend of $0.22 per Class A ordinary share. |
Recent fundamentally positive news (earnings, acquisitions, dividends) usually saw positive price reactions, with only one funding deal showing a negative 24h move.
Over the past few months, Royalty Pharma announced several value-focused events. An October Q4 2025 dividend declaration and a November AMVUTTRA royalty acquisition for $310M both saw positive next-day moves. Strong Q3 2025 results with $814M Portfolio Receipts and raised $3.20B–$3.25B guidance also aligned with a positive reaction. A December $275M Denali royalty funding agreement drew a modestly negative response. Prior November conference participation, similar to today’s, coincided with a small gain of 0.76%.
Market Pulse Summary
This announcement outlines Royalty Pharma’s participation in two December investor conferences, with webcasts available and archived for at least 30 days. Similar conference headlines earlier in 2025 generally produced modest stock moves, suggesting they serve more as investor-relations touchpoints than major catalysts. In assessing this news, investors may focus more on recent earnings, royalty acquisitions, and funding agreements, which historically had clearer price impacts than conference scheduling alone.
AI-generated analysis. Not financial advice.
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
- Citi’s 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET
- Evercore’s 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) present at the Citi 2025 Global Healthcare Conference?
What time is Royalty Pharma (RPRX) scheduled to speak at Evercore’s 8th Annual Healthcare Conference?
How can investors watch the Royalty Pharma (RPRX) conference webcasts?
For how long will Royalty Pharma (RPRX) archive the conference webcasts?
Will Royalty Pharma (RPRX) provide slides or a replay for the December 2025 presentations?
Where can I find the schedule and links for Royalty Pharma’s (RPRX) December investor presentations?
